Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.33 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349605 | 0.85 | HCAR1 (0.33) | — | |
| SCHEMBL31349609 | 0.77 | FFAR1 (0.34) | — | |
| SCHEMBL31698068 | 0.74 | ABL1 (0.37) | ESR2ESR1 | |
| SCHEMBL25316223 | 0.66 | AR (0.42) | AR | |
| SCHEMBL30507171 | 0.66 | AR (0.42) | AR | |
| SCHEMBL31436512 | 0.66 | ESR2 (0.30) | ESR2 | |
| SCHEMBL31349584 | 0.64 | MAP3K12 (0.36) | ESR2ESR1 | |
| SCHEMBL8721690 | 0.62 | CYP1A2 (0.40) | — | |
| SCHEMBL31698452 | 0.60 | AR (0.41) | AR | |
| SCHEMBL25318251 | 0.58 | PTGS2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |